Estimates of benefits and harms of prophylactic use of aspirin in the general population

Accumulating evidence supports an effect of aspirin in reducing overall cancer incidence and mortality in the general population. We reviewed current data and assessed the benefits and harms of prophylactic use of aspirin in the general population. The effect of aspirin for site-specific cancer inci...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Annals of oncology Ročník 26; číslo 1; s. 47 - 57
Hlavní autoři:	Cuzick, J, Thorat, M A, Bosetti, C, Brown, P H, Burn, J, Cook, N R, Ford, L G, Jacobs, E J, Jankowski, J A, La Vecchia, C, Law, M, Meyskens, F, Rothwell, P M, Senn, H J, Umar, A
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England 01.01.2015
Témata:	Anti-Inflammatory Agents, Non-Steroidal - adverse effects Anti-Inflammatory Agents, Non-Steroidal - therapeutic use Aspirin - adverse effects Aspirin - therapeutic use Female Gastrointestinal Hemorrhage - chemically induced Humans Male Myocardial Infarction - prevention & control Neoplasms - prevention & control Stroke - prevention & control cardiovascular disease aspirin cancer prevention benefit-harm gastrointestinal bleeding
ISSN:	1569-8041, 1569-8041
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Abstract	Accumulating evidence supports an effect of aspirin in reducing overall cancer incidence and mortality in the general population. We reviewed current data and assessed the benefits and harms of prophylactic use of aspirin in the general population. The effect of aspirin for site-specific cancer incidence and mortality, cardiovascular events was collated from the most recent systematic reviews. Studies identified through systematic Medline search provided data regarding harmful effects of aspirin and baseline rates of harms like gastrointestinal bleeding and peptic ulcer. The effects of aspirin on cancer are not apparent until at least 3 years after the start of use, and some benefits are sustained for several years after cessation in long-term users. No differences between low and standard doses of aspirin are observed, but there were no direct comparisons. Higher doses do not appear to confer additional benefit but increase toxicities. Excess bleeding is the most important harm associated with aspirin use, and its risk and fatality rate increases with age. For average-risk individuals aged 50-65 years taking aspirin for 10 years, there would be a relative reduction of between 7% (women) and 9% (men) in the number of cancer, myocardial infarction or stroke events over a 15-year period and an overall 4% relative reduction in all deaths over a 20-year period. Prophylactic aspirin use for a minimum of 5 years at doses between 75 and 325 mg/day appears to have favourable benefit-harm profile; longer use is likely to have greater benefits. Further research is needed to determine the optimum dose and duration of use, to identify individuals at increased risk of bleeding, and to test effectiveness of Helicobacter pylori screening-eradication before starting aspirin prophylaxis.
AbstractList	Accumulating evidence supports an effect of aspirin in reducing overall cancer incidence and mortality in the general population. We reviewed current data and assessed the benefits and harms of prophylactic use of aspirin in the general population.BACKGROUNDAccumulating evidence supports an effect of aspirin in reducing overall cancer incidence and mortality in the general population. We reviewed current data and assessed the benefits and harms of prophylactic use of aspirin in the general population.The effect of aspirin for site-specific cancer incidence and mortality, cardiovascular events was collated from the most recent systematic reviews. Studies identified through systematic Medline search provided data regarding harmful effects of aspirin and baseline rates of harms like gastrointestinal bleeding and peptic ulcer.METHODSThe effect of aspirin for site-specific cancer incidence and mortality, cardiovascular events was collated from the most recent systematic reviews. Studies identified through systematic Medline search provided data regarding harmful effects of aspirin and baseline rates of harms like gastrointestinal bleeding and peptic ulcer.The effects of aspirin on cancer are not apparent until at least 3 years after the start of use, and some benefits are sustained for several years after cessation in long-term users. No differences between low and standard doses of aspirin are observed, but there were no direct comparisons. Higher doses do not appear to confer additional benefit but increase toxicities. Excess bleeding is the most important harm associated with aspirin use, and its risk and fatality rate increases with age. For average-risk individuals aged 50-65 years taking aspirin for 10 years, there would be a relative reduction of between 7% (women) and 9% (men) in the number of cancer, myocardial infarction or stroke events over a 15-year period and an overall 4% relative reduction in all deaths over a 20-year period.RESULTSThe effects of aspirin on cancer are not apparent until at least 3 years after the start of use, and some benefits are sustained for several years after cessation in long-term users. No differences between low and standard doses of aspirin are observed, but there were no direct comparisons. Higher doses do not appear to confer additional benefit but increase toxicities. Excess bleeding is the most important harm associated with aspirin use, and its risk and fatality rate increases with age. For average-risk individuals aged 50-65 years taking aspirin for 10 years, there would be a relative reduction of between 7% (women) and 9% (men) in the number of cancer, myocardial infarction or stroke events over a 15-year period and an overall 4% relative reduction in all deaths over a 20-year period.Prophylactic aspirin use for a minimum of 5 years at doses between 75 and 325 mg/day appears to have favourable benefit-harm profile; longer use is likely to have greater benefits. Further research is needed to determine the optimum dose and duration of use, to identify individuals at increased risk of bleeding, and to test effectiveness of Helicobacter pylori screening-eradication before starting aspirin prophylaxis.CONCLUSIONSProphylactic aspirin use for a minimum of 5 years at doses between 75 and 325 mg/day appears to have favourable benefit-harm profile; longer use is likely to have greater benefits. Further research is needed to determine the optimum dose and duration of use, to identify individuals at increased risk of bleeding, and to test effectiveness of Helicobacter pylori screening-eradication before starting aspirin prophylaxis. BACKGROUNDAccumulating evidence supports an effect of aspirin in reducing overall cancer incidence and mortality in the general population. We reviewed current data and assessed the benefits and harms of prophylactic use of aspirin in the general population.METHODSThe effect of aspirin for site-specific cancer incidence and mortality, cardiovascular events was collated from the most recent systematic reviews. Studies identified through systematic Medline search provided data regarding harmful effects of aspirin and baseline rates of harms like gastrointestinal bleeding and peptic ulcer.RESULTSThe effects of aspirin on cancer are not apparent until at least 3 years after the start of use, and some benefits are sustained for several years after cessation in long-term users. No differences between low and standard doses of aspirin are observed, but there were no direct comparisons. Higher doses do not appear to confer additional benefit but increase toxicities. Excess bleeding is the most important harm associated with aspirin use, and its risk and fatality rate increases with age. For average-risk individuals aged 50-65 years taking aspirin for 10 years, there would be a relative reduction of between 7% (women) and 9% (men) in the number of cancer, myocardial infarction or stroke events over a 15-year period and an overall 4% relative reduction in all deaths over a 20-year period.CONCLUSIONSProphylactic aspirin use for a minimum of 5 years at doses between 75 and 325mg/day appears to have favourable benefit-harm profile; longer use is likely to have greater benefits. Further research is needed to determine the optimum dose and duration of use, to identify individuals at increased risk of bleeding, and to test effectiveness of Helicobacter pylori screening-eradication before starting aspirin prophylaxis. Accumulating evidence supports an effect of aspirin in reducing overall cancer incidence and mortality in the general population. We reviewed current data and assessed the benefits and harms of prophylactic use of aspirin in the general population. The effect of aspirin for site-specific cancer incidence and mortality, cardiovascular events was collated from the most recent systematic reviews. Studies identified through systematic Medline search provided data regarding harmful effects of aspirin and baseline rates of harms like gastrointestinal bleeding and peptic ulcer. The effects of aspirin on cancer are not apparent until at least 3 years after the start of use, and some benefits are sustained for several years after cessation in long-term users. No differences between low and standard doses of aspirin are observed, but there were no direct comparisons. Higher doses do not appear to confer additional benefit but increase toxicities. Excess bleeding is the most important harm associated with aspirin use, and its risk and fatality rate increases with age. For average-risk individuals aged 50-65 years taking aspirin for 10 years, there would be a relative reduction of between 7% (women) and 9% (men) in the number of cancer, myocardial infarction or stroke events over a 15-year period and an overall 4% relative reduction in all deaths over a 20-year period. Prophylactic aspirin use for a minimum of 5 years at doses between 75 and 325 mg/day appears to have favourable benefit-harm profile; longer use is likely to have greater benefits. Further research is needed to determine the optimum dose and duration of use, to identify individuals at increased risk of bleeding, and to test effectiveness of Helicobacter pylori screening-eradication before starting aspirin prophylaxis.
Author	Jacobs, E J La Vecchia, C Senn, H J Law, M Thorat, M A Rothwell, P M Brown, P H Cuzick, J Cook, N R Bosetti, C Umar, A Ford, L G Meyskens, F Burn, J Jankowski, J A
Author_xml	– sequence: 1 givenname: J surname: Cuzick fullname: Cuzick, J email: j.cuzick@qmul.ac.uk organization: Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK. Electronic address: j.cuzick@qmul.ac.uk – sequence: 2 givenname: M A surname: Thorat fullname: Thorat, M A organization: Centre for Cancer Prevention, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK – sequence: 3 givenname: C surname: Bosetti fullname: Bosetti, C organization: Department of Epidemiology, IRCCS-Istituto di Ricerche Farmacologiche 'Mario Negri', Milan, Italy – sequence: 4 givenname: P H surname: Brown fullname: Brown, P H organization: Department of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, USA – sequence: 5 givenname: J surname: Burn fullname: Burn, J organization: Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK – sequence: 6 givenname: N R surname: Cook fullname: Cook, N R organization: Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston – sequence: 7 givenname: L G surname: Ford fullname: Ford, L G organization: Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda – sequence: 8 givenname: E J surname: Jacobs fullname: Jacobs, E J organization: Epidemiology Research Program, American Cancer Society, Atlanta, USA – sequence: 9 givenname: J A surname: Jankowski fullname: Jankowski, J A organization: Centre for Biomedical Research-Translational and Stratified Medicine, Peninsula Schools of Medicine and Dentistry, Plymouth University, Plymouth; Centre for Digestive Diseases, Blizard Institute of Cell and Molecular Science, Queen Mary University of London, London, UK – sequence: 10 givenname: C surname: La Vecchia fullname: La Vecchia, C organization: Department of Epidemiology, IRCCS-Istituto di Ricerche Farmacologiche 'Mario Negri', Milan, Italy; Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy – sequence: 11 givenname: M surname: Law fullname: Law, M organization: Centre for Environmental and Preventive Medicine, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK – sequence: 12 givenname: F surname: Meyskens fullname: Meyskens, F organization: Chao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, USA – sequence: 13 givenname: P M surname: Rothwell fullname: Rothwell, P M organization: Stroke Prevention Research Unit, Nuffield Department of Clinical Neuroscience, University of Oxford, Oxford, UK – sequence: 14 givenname: H J surname: Senn fullname: Senn, H J organization: Tumor and Breast Center ZeTuP, St Gallen, Switzerland – sequence: 15 givenname: A surname: Umar fullname: Umar, A organization: Gastrointestinal and Other Cancers Research Group, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, USA
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/25096604$$D View this record in MEDLINE/PubMed
BookMark	eNqFkMtLxDAQxoOsuA89epUcvdTNu81RlvUBC14UvJVpkrqVNq1Netj_3qgreJMZmOE33wzDt0Qz33uH0CUlN5RovgafgFl3dmJMnqAFlUpnBRF09qefo2UI74QQpZk-Q3MmiVaKiAV63YbYdBBdwH2NK-dd3cSAwVu8h7H7psPYD_tDCyY2Bk_BfTEIQzM2HqeMe4ff0uIILR76YWohNr0_R6c1tMFdHOsKvdxtnzcP2e7p_nFzu8uM5CJmlnKmKqKgElAXqmCyLgqrLLNK5ELaXNam0mksnYSCg3aKAFeG29xqKSxboeufu-nLj8mFWHZNMK5twbt-CiXjkkpCRZ7_K6VKMiF0iiS9OkqnqnO2HMZk0ngof41jn8eXcrc
CitedBy_id	crossref_primary_10_1097_CEJ_0000000000000419 crossref_primary_10_1002_ijc_33323 crossref_primary_10_1097_PPO_0000000000000746 crossref_primary_10_1097_AOG_0000000000003304 crossref_primary_10_7326_M15_0039 crossref_primary_10_1016_j_jff_2020_103787 crossref_primary_10_1186_s13073_018_0520_y crossref_primary_10_1016_j_jcpo_2018_07_001 crossref_primary_10_1055_a_1771_6953 crossref_primary_10_1159_000529302 crossref_primary_10_1038_s41416_021_01354_5 crossref_primary_10_1053_j_seminoncol_2015_12_001 crossref_primary_10_1111_jth_13010 crossref_primary_10_1016_j_ypmed_2021_106872 crossref_primary_10_1096_fj_201600530R crossref_primary_10_1038_nrclinonc_2015_105 crossref_primary_10_1186_s12885_020_06810_8 crossref_primary_10_3389_fimmu_2018_00527 crossref_primary_10_1158_1535_7163_MCT_16_0074 crossref_primary_10_3390_ijms21239018 crossref_primary_10_1038_s41392_021_00658_5 crossref_primary_10_1177_1745506520961710 crossref_primary_10_1016_S0140_6736_17_33087_8 crossref_primary_10_3389_fonc_2018_00437 crossref_primary_10_1093_jnci_djx289 crossref_primary_10_2147_OTT_S281251 crossref_primary_10_1093_jnci_djv318 crossref_primary_10_1016_j_canep_2015_10_030 crossref_primary_10_3389_fmolb_2021_716735 crossref_primary_10_1093_emph_eow009 crossref_primary_10_1016_j_jss_2018_04_040 crossref_primary_10_1016_j_gore_2016_10_007 crossref_primary_10_1158_1940_6207_CAPR_20_0216 crossref_primary_10_3390_biomedicines5030043 crossref_primary_10_1002_ijc_29657 crossref_primary_10_1007_s10689_017_9986_9 crossref_primary_10_1158_1078_0432_CCR_16_0695 crossref_primary_10_1136_gutjnl_2017_315333 crossref_primary_10_3390_app9245552 crossref_primary_10_1016_j_pcad_2016_02_001 crossref_primary_10_1097_ACO_0000000000000200 crossref_primary_10_1038_s41416_023_02310_1 crossref_primary_10_1186_s12916_015_0493_2 crossref_primary_10_1038_s41416_022_02038_4 crossref_primary_10_1038_nrclinonc_2016_217 crossref_primary_10_1016_j_jacc_2016_05_083 crossref_primary_10_1002_lary_27114 crossref_primary_10_1093_jnci_djad231 crossref_primary_10_7554_eLife_06266 crossref_primary_10_1080_15685551_2020_1845428 crossref_primary_10_1097_MCG_0000000000001106 crossref_primary_10_1080_07388551_2020_1869687 crossref_primary_10_1007_s12020_015_0668_9 crossref_primary_10_1136_bmjopen_2023_078703 crossref_primary_10_3390_antiox14010029 crossref_primary_10_3390_cancers11111639 crossref_primary_10_1097_CEJ_0000000000000349 crossref_primary_10_2147_IJGM_S384375 crossref_primary_10_1177_0300060516686515 crossref_primary_10_12688_f1000research_6684_1 crossref_primary_10_1038_s41416_018_0039_4 crossref_primary_10_1080_01635581_2022_2108467 crossref_primary_10_1158_1940_6207_CAPR_22_0014 crossref_primary_10_1016_j_jss_2020_06_017 crossref_primary_10_1007_s10555_017_9678_9 crossref_primary_10_15430_JCP_25_007 crossref_primary_10_1111_eci_13973 crossref_primary_10_1053_j_gastro_2015_11_018 crossref_primary_10_1007_s10552_016_0785_7 crossref_primary_10_1200_JCO_2014_58_7592 crossref_primary_10_1053_j_gastro_2016_07_030 crossref_primary_10_1016_j_bbi_2024_07_023 crossref_primary_10_1177_0969141316650712 crossref_primary_10_1093_jncics_pkab005 crossref_primary_10_1093_jnci_djy100 crossref_primary_10_7861_clinmed_ed_20_1_harv crossref_primary_10_1002_ijc_33022 crossref_primary_10_1093_neuonc_noz123 crossref_primary_10_1016_j_compchemeng_2022_107704 crossref_primary_10_1093_annonc_mdv392 crossref_primary_10_34175_jno202002003 crossref_primary_10_1053_j_gastro_2015_09_010 crossref_primary_10_1007_s00108_018_0541_z crossref_primary_10_1158_1940_6207_CAPR_14_0469 crossref_primary_10_1186_s12915_017_0364_8 crossref_primary_10_1002_jcb_25544 crossref_primary_10_1016_j_prostaglandins_2015_07_004 crossref_primary_10_1093_jnci_djx267 crossref_primary_10_3389_fnut_2021_717343 crossref_primary_10_1016_j_mpmed_2015_03_006 crossref_primary_10_1155_2016_7230626 crossref_primary_10_1002_adfm_202211846 crossref_primary_10_1016_j_phymed_2017_08_002 crossref_primary_10_3390_cancers15010097 crossref_primary_10_3389_fonc_2023_1099811 crossref_primary_10_1360_SSV_2024_0029 crossref_primary_10_1097_MJT_0000000000001042 crossref_primary_10_1001_jama_2022_3385 crossref_primary_10_1111_all_12629 crossref_primary_10_1158_1940_6207_CAPR_20_0274 crossref_primary_10_3390_molecules28155759 crossref_primary_10_1016_j_cmet_2019_01_018 crossref_primary_10_1016_j_ceb_2016_07_010 crossref_primary_10_2147_IJGM_S391259 crossref_primary_10_1007_s00109_024_02430_y crossref_primary_10_1186_s12885_020_06983_2 crossref_primary_10_3390_cells7100157 crossref_primary_10_1097_MD_0000000000017382 crossref_primary_10_1001_jamanetworkopen_2019_16729 crossref_primary_10_1093_annonc_mdu546 crossref_primary_10_1007_s00134_019_05711_0 crossref_primary_10_1016_j_critrevonc_2016_05_011 crossref_primary_10_1016_j_biopha_2018_11_082 crossref_primary_10_1007_s10072_015_2412_x crossref_primary_10_1016_j_phrs_2019_104585 crossref_primary_10_1016_j_giec_2025_05_004 crossref_primary_10_1016_j_heliyon_2025_e42055 crossref_primary_10_1016_j_bbadis_2017_09_005 crossref_primary_10_1172_JCI83024 crossref_primary_10_1002_ijc_30108 crossref_primary_10_1038_ajg_2017_212 crossref_primary_10_1016_S0140_6736_18_31388_6 crossref_primary_10_1016_j_clon_2015_11_008 crossref_primary_10_1016_j_ebiom_2016_03_018 crossref_primary_10_1016_S2468_1253_19_30289_4 crossref_primary_10_1016_j_diabres_2018_01_026 crossref_primary_10_1016_j_esmogo_2024_100112 crossref_primary_10_1093_bmb_ldw028 crossref_primary_10_1186_s13053_022_00235_z crossref_primary_10_1093_jnci_djv385 crossref_primary_10_1002_ijc_32083 crossref_primary_10_3390_cancers15041282 crossref_primary_10_1093_annonc_mdu538 crossref_primary_10_3390_biom11050705 crossref_primary_10_3389_fphar_2016_00440 crossref_primary_10_1016_S0140_6736_18_31775_6 crossref_primary_10_1007_BF03652752 crossref_primary_10_1001_jamanetworkopen_2020_32072 crossref_primary_10_1186_s13063_020_4083_z crossref_primary_10_1016_S1470_2045_17_30536_3 crossref_primary_10_4331_wjbc_v7_i1_88 crossref_primary_10_1158_1940_6207_CAPR_17_0282 crossref_primary_10_1016_j_ebiom_2019_10_038 crossref_primary_10_1111_cas_15734 crossref_primary_10_1007_s10555_018_9755_8 crossref_primary_10_1016_j_critrevonc_2018_01_010 crossref_primary_10_1038_s41598_019_39489_4 crossref_primary_10_1111_bph_14196 crossref_primary_10_1002_rth2_12097 crossref_primary_10_1016_j_canep_2015_07_002 crossref_primary_10_3390_cancers13030406 crossref_primary_10_1016_S0140_6736_20_30366_4 crossref_primary_10_1007_s40256_014_0100_5 crossref_primary_10_1016_j_jaapos_2018_12_008 crossref_primary_10_2174_0929867324666170920144130 crossref_primary_10_1371_journal_pone_0160046 crossref_primary_10_1016_j_indcrop_2022_116081 crossref_primary_10_1016_j_maturitas_2017_03_001 crossref_primary_10_1007_s11888_016_0306_9 crossref_primary_10_1093_nsr_nwv054 crossref_primary_10_1007_s40271_021_00506_2 crossref_primary_10_1016_j_gene_2017_04_041 crossref_primary_10_1002_pds_4870 crossref_primary_10_1111_ans_13392 crossref_primary_10_1039_D3BM00509G crossref_primary_10_1038_s44276_024_00102_5 crossref_primary_10_1007_s00109_020_01963_2 crossref_primary_10_1016_j_canep_2015_08_003 crossref_primary_10_1080_13697137_2018_1455823 crossref_primary_10_3892_ijmm_2018_3883 crossref_primary_10_1016_j_bbadis_2017_01_011 crossref_primary_10_1111_nyas_14350 crossref_primary_10_1186_s12916_016_0648_9 crossref_primary_10_3389_fimmu_2024_1438235 crossref_primary_10_1136_bmjopen_2018_021869 crossref_primary_10_1093_annonc_mdy033 crossref_primary_10_1038_s41568_018_0081_9 crossref_primary_10_1093_annonc_mdu578 crossref_primary_10_1093_fampra_cmad042 crossref_primary_10_1002_1878_0261_12461 crossref_primary_10_1002_cpt_1447 crossref_primary_10_1182_blood_2017_05_743187 crossref_primary_10_1093_cvr_cvz233 crossref_primary_10_1158_1940_6207_CAPR_16_0241 crossref_primary_10_1016_j_archger_2021_104497 crossref_primary_10_1007_s10552_019_01252_5 crossref_primary_10_3390_molecules25092243 crossref_primary_10_1016_j_annonc_2020_02_012 crossref_primary_10_1136_ijgc_2021_002810 crossref_primary_10_1158_1078_0432_CCR_14_0877 crossref_primary_10_1002_hed_25518 crossref_primary_10_1053_j_seminoncol_2015_09_011 crossref_primary_10_1124_mol_115_098616 crossref_primary_10_1053_j_seminoncol_2015_09_010 crossref_primary_10_1136_bmjgast_2020_000453 crossref_primary_10_1016_j_bcp_2020_113895 crossref_primary_10_1016_S0140_6736_14_61622_6 crossref_primary_10_1038_nrclinonc_2015_169 crossref_primary_10_2147_JIR_S452670 crossref_primary_10_1186_s13063_021_05365_8 crossref_primary_10_1038_s41575_020_00368_3 crossref_primary_10_3390_ijms25105150 crossref_primary_10_1016_j_ypmed_2018_09_015 crossref_primary_10_1186_s12876_018_0759_1 crossref_primary_10_1053_j_gastro_2016_04_013 crossref_primary_10_1093_carcin_bgz195 crossref_primary_10_7326_M17_3085 crossref_primary_10_1186_s13063_024_08455_5 crossref_primary_10_1002_cncr_30004 crossref_primary_10_1016_j_ygyno_2015_12_009 crossref_primary_10_3390_ijms19041246 crossref_primary_10_1016_j_breastdis_2015_01_027 crossref_primary_10_1002_ijc_33311 crossref_primary_10_1016_j_canep_2015_04_012 crossref_primary_10_1016_j_ypmed_2015_04_014 crossref_primary_10_1016_j_ejim_2017_05_017
ContentType	Journal Article
Copyright	The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
Copyright_xml	– notice: The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1093/annonc/mdu225
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine
EISSN	1569-8041
EndPage	57
ExternalDocumentID	25096604
Genre	Research Support, Non-U.S. Gov't Journal Article Review
GrantInformation_xml	– fundername: Wellcome Trust grantid: 095626 – fundername: Cancer Research UK grantid: 16891 – fundername: British Heart Foundation – fundername: Cancer Research UK grantid: 15934 – fundername: Medical Research Council grantid: G0100496
GroupedDBID	--- -E4 .2P .86 .I3 .XZ .ZR 08P 0R~ 0U7 1TH 23M 2WC 4.4 482 53G 5GY 5VS 5WA 6J9 70D AAEDW AAGQS AAJKP AAJQQ AAKAS AAKUH AALRI AAMVS AAOGV AAPNW AAUQX AAXUO AAYWO ABEUO ABIXL ABJNI ABKDP ABLJU ABNGD ABNKS ABOCM ABQLI ABSMQ ABZBJ ACGFO ACGFS ACPQN ACPRK ACUKT ACUTO ACVFH ADBBV ADCNI ADEYI ADHKW ADHZD ADOCK ADRTK ADVLN ADYVW ADZCM ADZXQ AEGPL AEGXH AEHUL AEJOX AEKPW AEKSI AEMDU AENEX AENZO AEPUE AEUPX AEWNT AFETI AFIYH AFJKZ AFOFC AFPUW AFSHK AGCQF AGINJ AGKEF AGKRT AGQPQ AGSYK AHMBA AHXPO AIAGR AIGII AIJHB AITUG AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS ALUQC AMRAJ APIBT APWMN APXCP AQKUS ASPBG ATTQO AVWKF AXUDD AZFZN BAWUL BAYMD BGNMA BHONS BTRTY BVRKM BZKNY C1A CAG CDBKE CGR CKLRP COF CS3 CUY CVF CZ4 DAKXR DIK DILTD DL5 D~K E3Z EBS ECM EE~ EFKBS EIF EJD EX3 FDB FEDTE GJXCC GX1 H13 H5~ HVGLF HW0 HZ~ I09 IH2 IHE J21 KAQDR KDC KOM LAK M-Z M41 M4Y MBLQV MHKGH N9A NGC NOYVH NPM NTWIH NU0 NVLIB O9- OAWHX ODMLO OJQWA OK1 OVD P2P P6G PAFKI PB- PEELM PQQKQ Q1. Q5Y QBD R44 RD5 RNI ROL RPX RW1 RZC RZE RZF RZO SDH TCURE TEORI TR2 U2A W8F WOQ WOW X7H YAYTL YFH YKOAZ ZKX ZXP ~91 7X8
ID	FETCH-LOGICAL-c534t-d1326b06ab4af86825f88d6d2d64745d75fcb96ab5e5a83a9e60a36c3d7d954d2
IEDL.DBID	7X8
ISICitedReferencesCount	224
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000347416300008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1569-8041
IngestDate	Sun Nov 09 11:30:07 EST 2025 Thu Oct 02 11:50:23 EDT 2025 Mon Jul 21 06:05:58 EDT 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Keywords	cardiovascular disease aspirin cancer prevention benefit-harm gastrointestinal bleeding
Language	English
License	The Author 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c534t-d1326b06ab4af86825f88d6d2d64745d75fcb96ab5e5a83a9e60a36c3d7d954d2
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 ObjectType-Article-2 ObjectType-Feature-3 ObjectType-Review-1
OpenAccessLink	http://www.annalsofoncology.org/article/S0923753419313146/pdf
PMID	25096604
PQID	1652449494
PQPubID	23479
PageCount	11
ParticipantIDs	proquest_miscellaneous_2351501477 proquest_miscellaneous_1652449494 pubmed_primary_25096604
PublicationCentury	2000
PublicationDate	2015-01-01
PublicationDateYYYYMMDD	2015-01-01
PublicationDate_xml	– month: 01 year: 2015 text: 2015-01-01 day: 01
PublicationDecade	2010
PublicationPlace	England
PublicationPlace_xml	– name: England
PublicationTitle	Annals of oncology
PublicationTitleAlternate	Ann Oncol
PublicationYear	2015
References	25098322 - BMJ. 2014 Aug 05;349:g5037. doi: 10.1136/bmj.g5037. 25416686 - Ann Oncol. 2015 Feb;26(2):441-2. doi: 10.1093/annonc/mdu538. 25403580 - Ann Oncol. 2015 Feb;26(2):442-3. doi: 10.1093/annonc/mdu546.
References_xml	– reference: 25403580 - Ann Oncol. 2015 Feb;26(2):442-3. doi: 10.1093/annonc/mdu546. – reference: 25416686 - Ann Oncol. 2015 Feb;26(2):441-2. doi: 10.1093/annonc/mdu538. – reference: 25098322 - BMJ. 2014 Aug 05;349:g5037. doi: 10.1136/bmj.g5037.
SSID	ssj0006929
Score	2.5953457
SecondaryResourceType	review_article
Snippet	Accumulating evidence supports an effect of aspirin in reducing overall cancer incidence and mortality in the general population. We reviewed current data and... BACKGROUNDAccumulating evidence supports an effect of aspirin in reducing overall cancer incidence and mortality in the general population. We reviewed current...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	47
SubjectTerms	Anti-Inflammatory Agents, Non-Steroidal - adverse effects Anti-Inflammatory Agents, Non-Steroidal - therapeutic use Aspirin - adverse effects Aspirin - therapeutic use Female Gastrointestinal Hemorrhage - chemically induced Humans Male Myocardial Infarction - prevention & control Neoplasms - prevention & control Stroke - prevention & control
Title	Estimates of benefits and harms of prophylactic use of aspirin in the general population
URI	https://www.ncbi.nlm.nih.gov/pubmed/25096604 https://www.proquest.com/docview/1652449494 https://www.proquest.com/docview/2351501477
Volume	26
WOSCitedRecordID	wos000347416300008&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEB7Uinjx_agvVvAaTDf7yklEWjzY0oNKbmGT3ZWCJtW0_n5nk9SeCoIk5LBJSJjM7Hwzk_0G4IZ5HxN5otscIx2WSReoLFMBD62QEh1cXC-Pfn2So5FKknjcJtyq9rfKxZxYT9SmzH2O_JZG6HkRz0t5N_0MfNcoX11tW2isQydCKOO1WiZLtnCBvr_l1cTA3Td2KYscI_05pXw1oqw9y2D3v--0BzstpiT3jRLsw5otDmBr2FbNDyHpox1_eFBJSkcynN3cZFYRXRjiiavrUXwyCvy9XjJF5pX1Y9pX4ScFwR1hInlrGKrJ9Lfn1xG8DPrPD49B21EhyHnEZoHB2FNkodAZ004JjA6dUkYYagSTjBvJXZ7FeJpbrlWkYytCHYk8MtLEnBl6DBsoQ3sKhCljhLOUego9ypRmCDU41xLNWque7cL1QmYpaqwvQ-jClvMq7QmOmCLGbfU1S8l24aT5OOm0od9IqWesESE7-8Pd57CNCIc3OZML6Di0aXsJm_n3bFJ9XdXqgsfRePgDTnTMUQ
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Estimates+of+benefits+and+harms+of+prophylactic+use+of+aspirin+in+the+general+population&rft.jtitle=Annals+of+oncology&rft.au=Cuzick%2C+J&rft.au=Thorat%2C+M+A&rft.au=Bosetti%2C+C&rft.au=Brown%2C+P+H&rft.date=2015-01-01&rft.eissn=1569-8041&rft.volume=26&rft.issue=1&rft.spage=47&rft_id=info:doi/10.1093%2Fannonc%2Fmdu225&rft_id=info%3Apmid%2F25096604&rft_id=info%3Apmid%2F25096604&rft.externalDocID=25096604
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1569-8041&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1569-8041&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1569-8041&client=summon